Hypertension, Intracerebral Hemorrhage, Stroke
Conditions
Keywords
cerebral hemorrhage, intracerebral hemorrhage, stroke, hypertension, blood pressure, nicardipine, antihypertensive agent, hematoma expansion
Brief summary
The purpose of this trial is to evaluate the safety and effectiveness of lowering blood pressure using nicardipine in persons with acute hypertension associated with intracerebral hemorrhage.
Detailed description
An estimated 37,000 to 52,400 people in the United States have intracerebral hemorrhage (ICH) every year. ICH--a form of stroke that has poor outcome and is difficult to treat--is associated with the highest mortality rate of all strokes. Hematoma expansion has been identified as the most common cause of neurological deterioration in persons with ICH. Early evidence suggests that acute hypertension (HTN)-or elevated blood pressure-may make some individuals more susceptible to hematoma expansion. Treating HTN acutely may prevent hematoma expansion, however, the effect of aggressive HTN treatment has not been determined. The purpose of this trial is to evaluate the treatment feasibility and safety of lowering blood pressure using nicardipine--an antihypertensive medication--in persons who have acute HTN associated with ICH. This pilot study will enroll 60 individuals who qualify with a presenting systolic blood pressure of at least 170 mmHg, have an ICH, and can be evaluated and treatment initiated within 6 hours of onset of stroke symptoms. In a stepwise fashion, the scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine at 3 sequential levels: 170 to 200 mmHg, 140 to 170 mmHg, and 110 to 140 mmHg. Twenty participants will be enrolled per level. Treatment will last 18 to 24 hours. Participants will stay in the hospital for about 7 days (including 24 hours in the intensive care unit for close monitoring) and will return for 1-hour follow-up visits at 30 days and at 90 days after discharge from the hospital. During these visits participants will receive neurological assessments to determine their functional outcome. For participants, the study will be completed after the 90-day follow-up visit.
Interventions
DRUGnicardipine
Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours. * Started at 5mg/h * Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
University of Minnesota
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open treatment assignment was employed because it is not safe to conceal SBP measurement. Patient data routinely entered by clinical staff were used to evaluate safety.
Intervention model description
Staged intensity levels of rapid intravenous antihypertensive control for elevated SBP in patients with intracerebral hemorrhage were implemented in 3 sequential treatment arms to assess the feasibility and tolerability (safety) of this treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age older than 18 years. * Onset of new neurological signs of a stroke within 12 hours of the time to evaluation AND initiation of treatment with intravenous nicardipine. * Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect. * The total GCS score is greater than 8 at the time of enrollment. * CT scan demonstrates intraparenchymal hematoma with manual hematoma volume measurement less than 60 cc. * ICH is supratentorial and is located in lobar, basal ganglionic, or thalamic based on the initial CT scan appearance. * Admission systolic blood pressure greater than 170 mm Hg on two repeat measurements at least 5 minutes apart. * Evidence of chronic hypertension. * Subject is not considered a surgical candidate by the neurosurgery service.
Exclusion criteria
* Time of symptom onset cannot be reliably assessed. * Previously known neoplasms, arteriovenous malformation, or aneurysms. * Intracerebral hematoma considered to be related to trauma by the neurologist or neurosurgeon. * ICH is located in the cortex or infratentorial regions such as pons or cerebellum. * Blood is visualized in the subarachnoid space. * Intravenous nicardipine cannot be initiated within 12 hours of symptom onset. * Use of clonidine hydrochloride and other central alpha-agonist within the last 48 hours that have the potential of withdrawal hypertension. * Pregnancy, lactation, or parturition within previous 30 days. * Any history of bleeding diathesis or coagulopathy, including the use of warfarin. * Use of heparin in the previous 48 hours and a prolonged partial thromboplastin time. * Known atrial-ventricular heart block other than first degree, or sick sinus syndrome without a pacemaker. * Intolerance to calcium channel blockers. * Exposure to study medication in the preceding 24 hours prior to enrollment. * A platelet counts less than 100 000/mm3. * Major surgery within the previous six weeks. * History of any intracranial hemorrhage (including intracerebral or subarachnoid hemorrhage) or hemorrhagic stroke. * Seizure at onset of stroke. * Blood glucose less than 50 mg/dL or greater than 400 mg/dL. * Current participation in another research drug treatment protocol. * Isolated ventricular blood on CT scan. * Subject has a living will that precludes aggressive intensive care unit management. * Subject has acute myocardial infarction or renal failure that precludes use of aggressive antihypertensive therapy. * Subjects with unstable angina or acute myocardial infarction within 2 weeks prior to ICH. * Subjects with renal insufficiency with serum creatinine greater than 2.0 mg/dl or on renal dialysis. * Sinus tachycardia exceeding 120 beats per minute or supraventricular tachycardia is observed during initial evaluation. * Ischemic stroke within 4 weeks of presentation. * Congestive heart failure graded as class III and IV by New York Heart Association (NYHA) classification.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total Number of Serious Adverse Events Within the Initial 72 Hours From Treatment Per Subject | from treatment initiation through 72 hours | Serious adverse events were ascertained by site investigators using FDA-defined guidelines, defined as any untoward clinical events having been fatal, life-threatening, resulting in new or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage. Subjects were followed closely from randomization through 90 days. The initial 72-hour period was chosen as the most meaningful time period for which to examine SAEs likely to be related to the acute safety of the study treatment. |
| Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Within 3 hours of symptom onset and sustained through 18-24 hours. | Feasibility of treatment was assessed by whether SBP reduction and maintenance within the respective target range was achieved (treatment success) or not (treatment failure), and secondarily by whether a significant difference between treatment arms was achieved. Treatment failure was defined based on the observed hourly hourly minimum SBP remaining greater than the upper limit of the target range for 2 consecutive hours after initiation of nicardipine infusion. Spontaneous decline of SBP below the lower limit of the specific tier was not considered treatment failure as all such declines were asymptomatic.The lower number in the more intensive treatment groups reflects in part the greater challenge of rapidly lowering systolic blood pressure to a more intensive (lower) range, as a higher number of treatment failures as pre-defined by meeting the SBP range goal within 3 hours of symptom onset in this group predictably occurred. |
| Number of Participants With Neurological Deteriorations (Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score) During the 24 Hour Treatment, | within the first 72 hours of treatment initiation | Neurological status was monitored quantitatively and independently of other adverse events using two scales. The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. The National Institutes of Health Stroke Scale (NIHSS) quantifies neurologic deficits in 11 categories. Level of consciousness, horizontal eye movements, visual fields, facial palsy, movement in each limb, sensation, language and speech, and extinction or inattention on one side of the body are tested. Scores range from 0 to 42; 0 indicates normal function and higher scores indicate greater deficit severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | 3 months | The ability to maintain the Specified Systolic Blood Pressure Range for the 18-24 Hour Period without Neurological Deterioration or Side Effects |
Other
| Measure | Time frame | Description |
|---|---|---|
| Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | From enrollment through 3 months | The tolerability of the study treatment was further ascertained by examination of in-hospital, 1-month, or 3-month mortality in each treatment group. This pilot study was not powered (did not plan to enroll an adequate number of patients) to draw meaningful conclusions about individual adverse event categories, outcome measures, or to make comparisons between the treatment arms beyond the overall feasibility and tolerability of rapidly and significantly lowering SBP following intracerebral hemorrhage. The timing and magnitude of SBP reduction was also compared to the timing of individual safety events to further evaluate possible relationships between the study treatment, adverse events, and any recognizable safety concerns. This information is available in publication but is not able to be displayed on this website due to formatting restrictions. |
Countries
United States
Participant flow
Recruitment details
Patients 18 years and older presenting to site hospital ED and ICU areas within 6 hours of symptom onset for ≤ 60 cc volume intracerebral hemorrhage, with GCS ≥ 8, systolic blood pressure ≥ 170 mmHg and meeting all inclusion/exclusion criteria were enrolled following consent by themselves or a family member/legally authorized representative.
Pre-assignment details
A progressive, three-tiered approach to lowering systolic blood pressure with DSMB review after enrollment in each successive SBP range was completed. Safety was determined at each level before progressing to the next. Subjects meeting criteria and consenting to participate were considered enrolled and have been included in the data analysis.
Participants by arm
| Arm | Count |
|---|---|
| Tier 1 Dose escalation:
The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician.
nicardipine: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.
* Started at 5mg/h
* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued. | 18 |
| Tier 2 Dose escalation:
The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician.
nicardipine: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.
* Started at 5mg/h
* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued. | 20 |
| Tier 3 Dose escalation:
The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician.
nicardipine: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.
* Started at 5mg/h
* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued. | 22 |
| Total | 60 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 3 | 2 | 5 |
Baseline characteristics
| Characteristic | Total | Tier 1 | Tier 2 | Tier 3 |
|---|---|---|---|---|
| Age, Continuous | 62 years STANDARD_DEVIATION 15.1 | 62 years STANDARD_DEVIATION 17.7 | 58.5 years STANDARD_DEVIATION 13 | 65.1 years STANDARD_DEVIATION 14.6 |
| Baseline Measures of stroke symptom severity Initial GCS | 15 units on a scale | 14 units on a scale | 15 units on a scale | 15 units on a scale |
| Baseline Measures of stroke symptom severity Initial NIHSS score | 10 units on a scale | 11 units on a scale | 9 units on a scale | 8 units on a scale |
| Baseline Measures - Timing of Treatment Symptom onset to emergency department arrival | 1.72 hours STANDARD_DEVIATION 1.37 | 1.72 hours STANDARD_DEVIATION 1.27 | 1.70 hours STANDARD_DEVIATION 1.13 | 1.86 hours STANDARD_DEVIATION 1.78 |
| Baseline Measures - Timing of Treatment Symptom onset to treatment initiation | 4.19 hours STANDARD_DEVIATION 1.71 | 3.94 hours STANDARD_DEVIATION 1.45 | 4.13 hours STANDARD_DEVIATION 1.5 | 4.44 hours STANDARD_DEVIATION 2.08 |
| Duration of nicardipine infusion | 31.69 hours STANDARD_DEVIATION 30.75 | 12.93 hours STANDARD_DEVIATION 13.5 | 30.06 hours STANDARD_DEVIATION 23.8 | 45.82 hours STANDARD_DEVIATION 37.3 |
| Initial Hematoma Volume | 13.56 cubic centimeters STANDARD_DEVIATION 14.24 | 15.45 cubic centimeters STANDARD_DEVIATION 14.6 | 14.84 cubic centimeters STANDARD_DEVIATION 17.15 | 10.94 cubic centimeters STANDARD_DEVIATION 10.87 |
| Initial SBP | 208 millimeters of mercury (mmHg) | 209 millimeters of mercury (mmHg) | 212 millimeters of mercury (mmHg) | 201 millimeters of mercury (mmHg) |
| Maximum Dose of Nicardipine Used | 10.10 milligrams STANDARD_DEVIATION 5.98 | 8.47 milligrams STANDARD_DEVIATION 5.75 | 8.90 milligrams STANDARD_DEVIATION 4.48 | 12.52 milligrams STANDARD_DEVIATION 6.76 |
| Race/Ethnicity, Customized Black | 25 participants | 11 participants | 7 participants | 7 participants |
| Race/Ethnicity, Customized Others | 4 participants | 2 participants | 0 participants | 2 participants |
| Race/Ethnicity, Customized White | 31 participants | 5 participants | 13 participants | 13 participants |
| Region of Enrollment United States | 60 participants | 18 participants | 20 participants | 22 participants |
| Sex: Female, Male Female | 26 Participants | 9 Participants | 8 Participants | 9 Participants |
| Sex: Female, Male Male | 34 Participants | 9 Participants | 12 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 7 / 18 | 4 / 20 | 7 / 22 |
| serious Total, serious adverse events | 0 / 18 | 1 / 20 | 3 / 22 |
Outcome results
Primary
Number of Participants With Neurological Deteriorations (Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score) During the 24 Hour Treatment,
Neurological status was monitored quantitatively and independently of other adverse events using two scales. The Glasgow Coma Scale (GCS) score measures level of consciousness in eye, motor, and verbal components. At least one point is given in each category. The scale ranges from 3 to 15, with 3 indicating deep unconsciousness and 15 indicating consciousness is not impaired. The National Institutes of Health Stroke Scale (NIHSS) quantifies neurologic deficits in 11 categories. Level of consciousness, horizontal eye movements, visual fields, facial palsy, movement in each limb, sensation, language and speech, and extinction or inattention on one side of the body are tested. Scores range from 0 to 42; 0 indicates normal function and higher scores indicate greater deficit severity.
Time frame: within the first 72 hours of treatment initiation
Population: All subjects entered in the trial were followed and their data analyzed for safety measures. Not all subjects entered in the trial survived or remained in the trial to assess final outcomes at 1 or 3 months. When safety stopping rules could not have triggered after 18 initial subjects recruitment was adjusted to weight the subsequent tiers.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tier 1 | Number of Participants With Neurological Deteriorations (Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score) During the 24 Hour Treatment, | 1 participants |
| Tier 2 | Number of Participants With Neurological Deteriorations (Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score) During the 24 Hour Treatment, | 2 participants |
| Tier 3 | Number of Participants With Neurological Deteriorations (Decrease of 2 or More Points on the GCS Score or an Increase of 4 or More Points on the NIHSS Score) During the 24 Hour Treatment, | 4 participants |
Comparison: Done as a surrogate to evaluate the relationship between early SBP reduction and safety events.p-value: <0.5Wilcoxon rank sum test
Primary
Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier.
Feasibility of treatment was assessed by whether SBP reduction and maintenance within the respective target range was achieved (treatment success) or not (treatment failure), and secondarily by whether a significant difference between treatment arms was achieved. Treatment failure was defined based on the observed hourly hourly minimum SBP remaining greater than the upper limit of the target range for 2 consecutive hours after initiation of nicardipine infusion. Spontaneous decline of SBP below the lower limit of the specific tier was not considered treatment failure as all such declines were asymptomatic.The lower number in the more intensive treatment groups reflects in part the greater challenge of rapidly lowering systolic blood pressure to a more intensive (lower) range, as a higher number of treatment failures as pre-defined by meeting the SBP range goal within 3 hours of symptom onset in this group predictably occurred.
Time frame: Within 3 hours of symptom onset and sustained through 18-24 hours.
Population: All subjects were evaluated for achievement of the treatment goals.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tier 1 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Number treated within 3 hours of symptom onset | 7 participants |
| Tier 1 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Meeting Criteria of initial SBP > 170 mmHg | 18 participants |
| Tier 1 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Treatment Failure, SBP not in range by 2 hours | 0 participants |
| Tier 2 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Number treated within 3 hours of symptom onset | 5 participants |
| Tier 2 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Meeting Criteria of initial SBP > 170 mmHg | 20 participants |
| Tier 2 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Treatment Failure, SBP not in range by 2 hours | 0 participants |
| Tier 3 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Meeting Criteria of initial SBP > 170 mmHg | 22 participants |
| Tier 3 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Treatment Failure, SBP not in range by 2 hours | 9 participants |
| Tier 3 | Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. | Number treated within 3 hours of symptom onset | 6 participants |
Comparison: The hourly average (of maximum and minimum) SBP measurements were graphed with box-and-whiskers plot. In addition, a repeated measures analysis of the 25 average SBP (baseline and subsequent 24 hourly measures) was conducted with a mixed effects model (assuming autoregressive covariance structure in SAS version 9.1 PROC MIXED) to determine statistically the effect of treatment intensity (tier) on the average SBP over the 24 hrs with and without adjustment for baseline NIHSS score and age.p-value: <0.01repeated measure
Primary
Total Number of Serious Adverse Events Within the Initial 72 Hours From Treatment Per Subject
Serious adverse events were ascertained by site investigators using FDA-defined guidelines, defined as any untoward clinical events having been fatal, life-threatening, resulting in new or prolonged hospitalization, resulting in disability or congenital anomaly, or requiring intervention to prevent permanent impairment or damage. Subjects were followed closely from randomization through 90 days. The initial 72-hour period was chosen as the most meaningful time period for which to examine SAEs likely to be related to the acute safety of the study treatment.
Time frame: from treatment initiation through 72 hours
Population: All subjects entered in the trial were followed and their data analyzed for safety measures. Not all subjects entered in the trial survived or remained in the trial to assess final outcomes at 1 or 3 months. When safety stopping rules could not have triggered after 18 initial subjects recruitment was adjusted to weight the subsequent tiers.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tier 1 | Total Number of Serious Adverse Events Within the Initial 72 Hours From Treatment Per Subject | 0 Participants |
| Tier 2 | Total Number of Serious Adverse Events Within the Initial 72 Hours From Treatment Per Subject | 1 Participants |
| Tier 3 | Total Number of Serious Adverse Events Within the Initial 72 Hours From Treatment Per Subject | 3 Participants |
Secondary
Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals
The ability to maintain the Specified Systolic Blood Pressure Range for the 18-24 Hour Period without Neurological Deterioration or Side Effects
Time frame: 3 months
Population: All subjects were analyzed by treatment arm for the presence of SAEs, neurological deterioration, symptomatic or asymptomatic hematoma expansion, and mortality in-hospital or within 3 months. Pre-specified safety stopping rules were used. The nature and relatedness of events was examined and overseen by an external Data safety and Monitoring Board.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 1-month favorable outcome, mRS 0-2 | 4 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with asymptomatic hematoma expansion | 6 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month favorable outcome, mRS 0-2 | 8 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month mortality | 3 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with in-hospital mortality | 2 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with neurologic deterioration within 24 hours | 1 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with SAE within 72 hours | 0 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 1-month outcome assessment | 3 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with symptomatic hematoma expansion | 0 participants |
| Tier 1 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 3-month outcome assessment | 3 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with in-hospital mortality | 1 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with SAE within 72 hours | 1 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with neurologic deterioration within 24 hours | 2 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with symptomatic hematoma expansion | 1 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with asymptomatic hematoma expansion | 2 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 3-month outcome assessment | 4 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month mortality | 2 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 1-month favorable outcome, mRS 0-2 | 6 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 1-month outcome assessment | 3 participants |
| Tier 2 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month favorable outcome, mRS 0-2 | 9 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with symptomatic hematoma expansion | 4 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 3-month outcome assessment | 2 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 1-month favorable outcome, mRS 0-2 | 4 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with neurologic deterioration within 24 hours | 4 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month favorable outcome, mRS 0-2 | 7 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N missing for 1-month outcome assessment | 2 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with in-hospital mortality | 1 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with asymptomatic hematoma expansion | 3 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with SAE within 72 hours | 3 participants |
| Tier 3 | Particpants Who Tolerate Rapid Systolic Blood Pressure Reduction and Maintain Treatment Goals | N with 3-month mortality | 5 participants |
Other Pre-specified
Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death.
The tolerability of the study treatment was further ascertained by examination of in-hospital, 1-month, or 3-month mortality in each treatment group. This pilot study was not powered (did not plan to enroll an adequate number of patients) to draw meaningful conclusions about individual adverse event categories, outcome measures, or to make comparisons between the treatment arms beyond the overall feasibility and tolerability of rapidly and significantly lowering SBP following intracerebral hemorrhage. The timing and magnitude of SBP reduction was also compared to the timing of individual safety events to further evaluate possible relationships between the study treatment, adverse events, and any recognizable safety concerns. This information is available in publication but is not able to be displayed on this website due to formatting restrictions.
Time frame: From enrollment through 3 months
Population: Serious adverse events were monitored for all patients throughout the 3-month study period; when mortality resulted death was categorized as having occurred prior to or following hospital discharge. The 3-month mortality count includes deaths that occurred earlier. Survival was confirmed at hospital discharge, 1 month, and 3 months.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tier 1 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Mortality at 3 months (also in participant flow) | 3 Participants |
| Tier 1 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | In-hospital mortality | 2 Participants |
| Tier 1 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Survival/no known death at 1 or 3 months (derived) | 13 Participants |
| Tier 2 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Mortality at 3 months (also in participant flow) | 2 Participants |
| Tier 2 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | In-hospital mortality | 1 Participants |
| Tier 2 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Survival/no known death at 1 or 3 months (derived) | 17 Participants |
| Tier 3 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | In-hospital mortality | 1 Participants |
| Tier 3 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Survival/no known death at 1 or 3 months (derived) | 16 Participants |
| Tier 3 | Particpants Who Achieve Reduction of Blood Pressure and Maintain Treatment Goals (the Specified Systolic Blood Pressure Range for the 18-24 Hour Period) Without Neurological Deterioration or Side Effects Resulting in Death. | Mortality at 3 months (also in participant flow) | 5 Participants |